Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease
| Autor: | G. Luef, Werner Poewe, M. Emre, B. Kleedorfer |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Male
medicine.medical_specialty Parkinson's disease Nausea medicine.medical_treatment Administration Oral Dopamine agonist Receptors Dopamine Degenerative disease Internal medicine medicine Humans Parkinson Disease Secondary Aged Chemotherapy Dose-Response Relationship Drug business.industry Middle Aged medicine.disease Apomorphine Dose–response relationship Endocrinology Neurology Vomiting Aminoquinolines Female Neurology (clinical) medicine.symptom business medicine.drug |
| Zdroj: | Movement disorders : official journal of the Movement Disorder Society. 5(3) |
| ISSN: | 0885-3185 |
| Popis: | Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205-502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L-DOPA. CV 205-502, which combines structural features common to both ergolines and apomorphine, thus revealed interesting antiparkinsonian properties, but nausea and vomiting were dose-limiting side effects in all patients tested. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text